REGENXBIO Chairman Kenneth Mills Resigns From Board After Taking CEO Job Elsewhere
George Migausky, an independent director, becomes Chairman, and Daniel Tassé gives up the lead independent director role.
REGENXBIO Chairman Kenneth T. Mills resigned from the board on Wednesday, effective October 21, 2026, after becoming chief executive of another company, according to an 8-K the company filed Friday. The board named director George Migausky to succeed him as Chairman.
What the 8-K says
The filing, made under the item covering departures of directors and officers, says Mills recently became chief executive officer of another company and intends to focus his efforts on that role. It does not name the company.
The filing also says his decision was not related to any disagreement with REGENXBIO on any matter relating to its operations, policies, or practices.
Mills told the company of his resignation on Wednesday, the date of the event reported. The 8-K itself is dated Friday, October 16, 2026, and is signed by Patrick J. Christmas II, the company's Executive Vice President, Chief Strategy & Legal Officer.
What changes on the board
In connection with Mills' departure, the board appointed Migausky as Chairman. The filing describes him as an independent director.
That status triggers a second change. Under the company's Corporate Governance Guidelines, Daniel Tassé has stepped down as Lead Independent Director because the new Chairman is independent. Tassé stays on the board.
The filing does not describe any other change to the board's makeup.
The stock and the next date
REGENXBIO shares closed at $7.16 at Thursday's close, up 4.07% on the session, before the filing appeared Friday morning. That move came before the news, so it is not a reaction to it.
Mills' resignation takes effect October 21, 2026.
Mills' departure becomes effective October 21, 2026, with Migausky as Chairman and Tassé still on the board.
Sources
- 8-K Filing — REGENXBIO Inc. (RGNX) — SEC EDGAR
